Business Wire

CIRIUM

10.11.2021 09:02:15 CET | Business Wire | Press release

Share
New Airline CO2 Emissions Monitor From Cirium Reveals 40% Less Fuel Burnt From Flights Flown Globally In 2021

Cirium, the aviation analytics company, today launched its Global Aircraft Emissions Monitor, providing a highly accurate measure of CO2 emissions and fuel consumption from flights flown globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005600/en/

New insights from Cirium show that airlines have burnt 40% less fuel from flights in 2021 year-to-date compared to the same period in 2019.

The reduction in flight-produced carbon emissions is attributed to the drop in flights worldwide because of the dramatic impact that COVID-19 had on air travel. Flights tracked year-to-date are 29% down versus 2019.

The fuel burn has increased as domestic and international flights have started to return but not as much as expected compared to 2019—before the pandemic. The airlines have been flying their aircraft far fewer hours and prioritizing more efficient aircraft.

“To achieve the aggressive targets for aviation to reach net zero emissions by 2050, a thorough understanding is needed of all elements of an aircraft used for flights and the exact flight operations,” said Jeremy Bowen, CEO at Cirium.

“Cirium’s Global Aircraft Emissions Monitor boasts data of the highest quality and validity. The need for greater sustainability is clear and Cirium is committed to supporting the industry’s decision-making based on accurate carbon emissions tracking.”

The uniqueness of the product derives from the data, which is obtained from the widest and deepest data warehouse in the aviation industry. No other independent source can provide calculations based on the same blended data sets. The Monitor’s custom data calculations are based on hundreds of flight and aircraft variables for maximum accuracy. These variables include actual flight and taxi times, cabin configuration, aircraft operating empty weight, assumed cargo tonnage, aircraft/engine type, winglet equipage, aircraft age and more.

Tests conducted on the Global Aircraft Emissions Monitor have validated its accuracy in the order of 1%.

The Global Aircraft Emissions Monitor includes customized options for CO2 emissions and fuel consumption. It applies complete profiles of actual flights and aircraft, which are fused with block fuel burn models.

While aviation has reduced its emissions overall this year, travel is recovering, with Cirium forecasts projecting for global recovery to 2019 levels potentially by 2023. Cirium’s Fleet Forecast also predicts that based on the flight capacity of the increasing fleet to be in service by 2039, fuel burn may reach 485 million tons. This equates to 1,530 million tons of CO2 emissions, excluding any initiatives for sustainable aviation fuels (SAF) or offsetting.

Carbon emissions and fuel consumption from flights are increasingly becoming the centre focus for all airlines, airports aviation finance, aircraft manufacturers, air traffic management, government, and fuel providers.

The comprehensiveness of the Cirium Global Aircraft Emissions Monitor will enable organizations to track emissions as a measure of efficiency, understand aspects of total cost of ownership, understand the profile of a current operator, gain a better understanding of the climate impact, benchmark the competition, and create fuel demand models.

Find out more at https://cirium.com/EmissionsMonitor .

-End-

For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye